Novel antibodies target human receptors to neutralize SARS-CoV-2 variants and future sarbecoviruses NatureMicrobiol antibodies covid COVID19 SARSCoV2 variants sarbecovirus monoclonalantibodies
By Neha MathurMay 17 2023Reviewed by Lily Ramsey, LLM In a recent study published in the Nature Microbiology Journal, researchers generated six human monoclonal antibodies that prevented infection by all human angiotensin-converting enzyme 2 binding sarbecoviruses tested, including severe acute respiratory syndrome coronavirus 2 and its variants, Delta and Omicron.
Any new S-targeting mAb therapy will also probably have limited utility because SARS-CoV-2 will continue to adapt to human antibodies. Ideally, mAbs developed in anticipation of future pandemics caused by sarbecoviruses should be resilient to mutations that arise in them. Further, the team generated hybridomas from mice using sera that inhibited SARS-CoV-2 pseudotyped viruses. They used enzyme-linked immunosorbent assay to screen hybridoma supernatants for hACE2-binding mAbs.
They used single-particle cryo-electron microscopy to delineate the structural basis for broad neutralization of anti-hACE2 mAbs. These ten mAbs were 1C9H1, 4A12A4, 05B04, 2C12H3, 2F6A6, 2G7A1, 05D06, 05E10, 05G01 and 05H02. Four of the five mAbs from the KP AlivaMab mice, viz., 05B04, 05E10, 05G01, and 05D06, shared identical complementarity-determining regions . Conversely, AV AlivaMab mice-derived mAbs were diverse.
In addition, the anti-hACE2 mAbs showed favorable pharmacokinetics and no ill effects on the hACE2 knock-in mice. When used prophylactically in hACE2 knock-in mice, these mAbs conferred near-sterilizing protection against lung SARS-CoV-2 infection.The six anti-hACE2 mAbs also inhibited infection by pseudotyped SARS-CoV-2 variants, Delta, and Omicron, with similar potency, i.e., half maximal inhibitory concentration values ranging between 8.2 ng ml−1 and 197 ng ml−1.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Novel 'CLEVER' method accelerates engineering and genetic study of SARS-CoV-2 and its variantsNovel 'CLEVER' method accelerates engineering and genetic study of SARS-CoV-2 and its variants biorxivpreprint UniBasel_en genetics geneticengineering covid SARSCoV2 variants reversegentics
Consulte Mais informação »
Does obstructive sleep apnea increase the risk of post-acute sequelae of SARS-CoV-2?Research paper examines the potential link between obstructive sleep apnea (OSA) and Post-Acute Sequelae of SARS-CoV-2 (PASC), the long-term effects of COVID-19. It investigates whether OSA increases the risk of more severe PASC outcomes.
Consulte Mais informação »
Tracking SARS-CoV-2 in MozambiqueA new study co-led by ISGlobal, the Manhiça Health Research Centre (CISM) and the Instituto de Biomedicina de Valencia (IBV), used cutting-edge sequencing technology and phylogenetic analysis to study the second and third waves of COVID-19 in Mozambique. The results, published in The Lancet Global Health, show that the beta variant of SARS-CoV-2 arrived mainly from South Africa, while delta arrived mainly from the UK and India, in addition to South Africa.
Consulte Mais informação »
Study identifies two novel highly pathogenic avian influenza viruses (H5N1) clade 2.3.4.4b.2Study identifies two novel highly pathogenic avian influenza viruses (H5N1) clade 2.3.4.4b.2 CDCgov avianinfluenza avianflu virus H5N1 novel viral zoonotic transmission swans
Consulte Mais informação »
The discovery of a novel orthonairovirus from Dermacentor silvarum ticks near the China–North Korea borderThe discovery of a novel orthonairovirus from Dermacentor silvarum ticks near the China–North Korea border CDCgov ticks virus orthonairovirus china korea novelvirus transmission
Consulte Mais informação »
New study using novel approach for glioblastoma treatment shows promising results, extending survivalA new international study published in Nature Medicine and presented as a late-breaking abstract at the American Association of Neurological Surgeons (AANS) annual conference, shows great promise for patients with glioblastoma.
Consulte Mais informação »